This is a working overview of reference standard, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-23. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Sanger changed his research project to study the metabolism of lysine and a more practical problem concerning the nitrogen of potatoes. His thesis had the title, "The metabolism of the amino acid lysine in the animal body". He was examined by Charles Harington and Albert Charles Chibnall and awarded his doctorate in 1943.
==== Egypt ==== In an extension of a bilateral dispute between Ethiopia and Egypt over the Grand Ethiopian Renaissance Dam, Ethiopian government websites have been hacked by the Egypt-based hackers in June 2020.
=== Bu === John Buchanan (1917–2007). American biochemist at MIT, best known for his research on the biosynthesis of purines. Member Natl. Acad. Sci. USA. Eduard Buchner (1860–1917). German chemist and physiologist at LMU Munich, who overthrew the doctrine of vitalism by showing that cell-free yeast extract could catalyse fermentation, a discovery described by Arthur Kornberg as the beginning of biochemistry. 1907 Nobel Prize in Chemistry. Dean Burk (1904–1988). American biochemist at the Fixed Nitrogen Research Laboratory, co-discoverer of biotin. He is credited (with Hans Lineweaver) with introducing the double-reciprocal plot in kinetics. He became a vociferous opponent of water fluoridation. Robert H. Burris (1914–2010). American biochemist at the University of Wisconsin–Madison, expert on nitrogen fixation. Member Natl. Acad. Sci. USA. Stephen Busby (DPhil 1975) FRS, biochemist at the University of Birmingham. Carlos Bustamante (b. 1951). Peruvian-American biophysicist at UC Berkeley. Known for single-molecule studies, including the use of optical tweezers for measuring the forces that maintain biological structures. Member Natl. Acad. Sci. USA.
One example of how these changes have been used to study activities is the New York African Burial Ground in New York. This provides evidence of the brutal working conditions under which the enslaved labored; osteoarthritis of the vertebrae was common even among the young. The pattern of osteoarthritis combined with the early age of onset provides evidence of labor that resulted in mechanical strain to the neck. One male skeleton shows stress lesions at 37 percent of 33 muscle or ligament attachments, showing he experienced significant musculoskeletal stress. Overall, the interred show signs of significant musculoskeletal stress and heavy workloads, although workload and activities varied by individual. Some show high levels of stress, while others do not. This indicates the variety of types of labor (e.g., domestic vs. carrying heavy loads).
Sources: en.wikipedia.org
Some of the oldest forms of biologics are extracted from the bodies of animals, and other humans especially. Important biologics include: Whole blood and other blood components Organ transplantation and tissue transplants Stem-cell therapy Antibodies for passive immunity (e.g., to treat a virus infection) Human reproductive cells Human breast milk Fecal microbiota Some biologics that were previously extracted from animals, such as insulin, are now more commonly produced by recombinant DNA. Biologics can refer to a wide range of biological products in medicine. However, in most cases, the term is used more restrictively for a class of therapeutics (either approved or in development) that are produced using biological processes involving recombinant DNA technology. These medications are usually one of three types:
3-Arylpropiolonitriles (APN) belong to a class of electron-deficient alkyne derivatives substituted by two electron-withdrawing groups – a nitrile and an aryl moieties. Such activation results in improved selectivity towards highly reactive thiol-containing molecules, namely cysteine residues in proteins. APN-based modification of proteins was reported to surpass several important drawbacks of existing strategies in bioconjugation, notably the presence of side reactions with other nucleophilic amino acid residues and the relative instability of the resulting bioconjugates in the blood stream. The latter drawback is especially important for the preparation of targeted therapies, such as antibody-drug conjugates. The synthesis of 3-arylpropiolonitriles has been the subject of several studies. The most elaborated and often used approach is based on MnO2-mediated free radical oxidation of the corresponding propargylic alcohols obtained using Sonogashira coupling of the corresponding iodo-derivative in the presence of ammonia (Figure 1).
In April 2011, elevated levels of caesium-137 were also being found in the environment after the Fukushima Daiichi nuclear disasters in Japan. In July 2011, meat from 11 cows shipped to Tokyo from Fukushima Prefecture was found to have 1530 to 3200 becquerels per kilogram of 137Cs, considerably exceeding the Japanese legal limit of 500 becquerels per kilogram at that time. In March 2013, a fish caught near the plant had a record 740,000 becquerels per kilogram of radioactive caesium, above the 100 becquerels per kilogram government limit. A 2013 paper in Scientific Reports found that for a forest site 50 kilometres (30 miles) from the stricken plant, 137Cs concentrations were high in leaf litter, fungi and detritivores, but low in herbivores. By the end of 2014, "Fukushima-derived radiocaesium had spread into the whole western North Pacific Ocean", transported by the North Pacific current from Japan to the Gulf of Alaska. It has been measured in the ocean surface layer down to 200 meters (660 feet) and south of the current area down to 400 m (1,300 ft). Caesium-137 is reported to be the major health concern in Fukushima. A number of techniques are being considered that will be able to strip out 80% to 95% of the caesium from contaminated soil and other materials efficiently and without destroying the organic material in the soil. These include hydrothermal blasting.
== History == Lente insulin arose from research into ways to alter the pharmacokinetics of bovine or porcine insulin products. Prior to the late 1940s, insulin products were derived from pork or beef sources, and then used virtually unaltered as "short-acting" insulin products. It was known by 1950 that the addition of protamine or zinc could alter the duration of action of these insulin products, and in 1952, K. Hallas-Møller at Novo Nordisk produced the first commercial insulin zinc suspension for use in humans. For decades, lente insulin was used as a basal insulin, designed to mimic the body's continual slow release of insulin throughout the day. Compared to NPH insulin, lente insulin has a similar but more protracted loss of action after a dose is administered. In the 1990s, recombinant DNA technology allowed for the mass production of the human insulin protein in yeast or bacteria. This led to formulations of recombinant lente human insulin products by the early 2000s. However, lente insulin began to fall out of favor with doctors in the mid-2000s, when insulin analogues such as glargine began to be approved. Insulin analogues made by recombinant DNA production methods have less variation in their strength and purity between doses and batches. Furthermore, while lente insulin (and NPH) have a definitive peak in effect, insulin analogs have a much less pronounced peak, making for more predictable effects and less risk of hypoglycemia.
Ghana produces and exports hydrocarbons such as sweet crude oil and natural gas. The 100%-state-owned filling station company, Ghana Oil Company, is the number one petroleum and gas filling station, and the 100%-state-owned state oil company Ghana National Petroleum Corporation oversees hydrocarbon exploration and production of petroleum and natural gas reserves. Ghana aims to further increase the output of oil to 2.2 million barrels (350,000 m3) per day and gas to 34,000,000 cubic metres (1.2×10^9 cu ft) per day. The Jubilee Oil Field, which contains up to 3 billion barrels (480,000,000 m3) of sweet crude oil, was discovered in 2007. Ghana is believed to have up to 5 billion barrels (790,000,000 m3) to 7 billion barrels (1.1×109 m3) of petroleum in reserves, which is the fifth-largest in Africa and the 21st-to-25th-largest proven reserves in the world. It also has up to 1.7×1011 cubic metres (6×10^12 cu ft) of natural gas in reserves. The government has drawn up plans to nationalise petroleum and natural gas reserves to increase government revenue. In 2015, Ghana produced 88 metric tonnes of gold as per the Our World in Data report. As of 2019, Ghana was the 7th largest producer of gold in the world, producing ~140 tonnes that year. This record saw Ghana surpass South Africa in output for the first time, making Ghana the largest gold producer in Africa. In addition to gold, Ghana exports silver, timber, diamonds, bauxite, and manganese, and has other mineral deposits. Ghana ranks 9th in the world in diamond export and reserve size.
Sources: en.wikipedia.org
Electrotherapy is the use of electrical energy as a medical treatment. In medicine, the term electrotherapy can apply to a variety of treatments, including the use of electrical devices such as deep brain stimulators for neurological disease. Electrotherapy is a part of neurotherapy aimed at changing the neuronal activity. The term has also been applied specifically to the use of electric current to speed up wound healing. The use of electromagnetic stimulation (EMS) is also widespread for the treatment of muscular pain. Additionally, the term "electrotherapy" or "electromagnetic therapy" has also been applied to a range of alternative medical devices and treatments.
== External links == Video of the Daisy ad, from the PBS website A Historical Look at Campaign Commercials The Emergence of the Maimed Hero Spy vs Spy Gallery Missile Command at the Killer List of Videogames
The Vasa is a Swedish 1628 ship found archaeologically and was very well preserved. Completely submerged for 333 years allowed for the wood to be completely waterlogged but pollution in the 20th century off of the city Stockholm was able to kill any microorganisms that would have feast on the wreck, like the shipworm. Vasa was sprayed with a PEG solution for 17 years followed by a period of drying which is ongoing.
The rate of clearance is very slow among microglia in comparison to macrophages. Possible source for variations in clearance rates could include lack of opsonin activity around microglia, and the lack of increased permeability in the blood–brain barrier. The decreased permeability could further hinder macrophage infiltration to the site of injury. These findings have suggested that the delay in Wallerian degeneration in CNS in comparison to PNS is caused not due to a delay in axonal degeneration, but rather is due to the difference in clearance rates of myelin in CNS and PNS.
== Development == As with other antibody mimetics, the idea behind developing the Affibody molecule was to apply a combinatorial protein engineering approach on a small and robust protein scaffold. The aim was to generate new binders capable of specific binding to different target proteins with almost good affinity, while retaining the favorable folding and stability properties, and ease of bacterial expression of the parent molecule. The original Affibody protein scaffold was designed based on the Z domain (the immunoglobulin G binding domain) of protein A. These molecules are the newly developed class of scaffold proteins derived from the randomization of 13 amino acids located in two alpha helices involved in the binding activity of the parent protein domain. Lately, amino acids outside of the binding surface have been substituted in the scaffold to create a surface entirely different from the ancestral protein A domain. In contrast to antibodies, Affibody molecules are composed of alpha helices and lack disulfide bridges. The parent three-helix bundle structure is currently the fastest folding protein structure known. Specific Affibody molecules binding a desired target protein can be “fished out” from pools (libraries) containing billions of different variants, using phage display.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.